Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACETNASDAQ:AVTXNASDAQ:FBIONASDAQ:FWP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACETAdicet Bio$0.75-3.8%$0.65$0.45▼$1.70$62.06M1.67713,953 shs336,366 shsAVTXAvalo Therapeutics$4.84-0.8%$4.48$3.39▼$16.00$52.41M0.759,100 shs44,205 shsFBIOFortress Biotech$1.85-5.6%$1.73$1.33▼$2.89$54.70M1.76412,846 shs242,598 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/A10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACETAdicet Bio-0.62%+4.06%+16.75%-0.35%-44.29%AVTXAvalo Therapeutics+3.61%+12.70%+32.61%-33.96%-57.53%FBIOFortress Biotech-6.67%+4.26%+12.64%+17.37%-1.51%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACETAdicet Bio2.1878 of 5 stars3.32.00.00.02.61.70.6AVTXAvalo Therapeutics3.576 of 5 stars3.55.00.00.02.81.71.3FBIOFortress Biotech2.6033 of 5 stars3.51.00.00.02.73.30.6FWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACETAdicet Bio 2.60Moderate Buy$7.50899.60% UpsideAVTXAvalo Therapeutics 3.00Buy$30.00519.83% UpsideFBIOFortress Biotech 3.00Buy$21.001,035.14% UpsideFWPForward Pharma A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FWP, ACET, AVTX, and FBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.003/21/2025ACETAdicet BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/20/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$18.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACETAdicet Bio$24.99M2.48N/AN/A$2.43 per share0.31AVTXAvalo Therapeutics$441K118.84N/AN/A$9.11 per share0.53FBIOFortress Biotech$57.78M0.95N/AN/A$0.10 per share18.50FWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACETAdicet Bio-$142.66M-$1.30N/AN/AN/AN/A-53.85%-46.45%8/12/2025 (Estimated)AVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)FBIOFortress Biotech-$60.64M-$2.23N/AN/AN/A-84.53%N/A-34.93%8/12/2025 (Estimated)FWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALatest FWP, ACET, AVTX, and FBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/6/2025Q1 2025ACETAdicet Bio-$0.34-$0.31+$0.03-$0.31N/AN/A3/31/2025Q4 2024FBIOFortress Biotech-$0.79-$0.26+$0.53-$0.26$16.30 million$15.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACETAdicet Bio$0.045.33%N/AN/A N/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACETAdicet BioN/A10.6410.64AVTXAvalo TherapeuticsN/A1.421.42FBIOFortress BiotechN/A1.231.06FWPForward Pharma A/SN/A18.43N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACETAdicet Bio83.89%AVTXAvalo Therapeutics87.06%FBIOFortress Biotech96.51%FWPForward Pharma A/S12.57%Insider OwnershipCompanyInsider OwnershipACETAdicet Bio7.80%AVTXAvalo Therapeutics3.03%FBIOFortress Biotech27.90%FWPForward Pharma A/S71.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACETAdicet Bio9082.71 million66.66 millionOptionableAVTXAvalo Therapeutics4010.83 million10.37 millionNot OptionableFBIOFortress Biotech17029.57 million18.39 millionOptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableFWP, ACET, AVTX, and FBIO HeadlinesRecent News About These CompaniesInside Forward's failed attempt to revolutionize the doctor's officeNovember 14, 2024 | businessinsider.comPrimary care player Forward shutters after raising $400M, rolling out CarePodsNovember 13, 2024 | fiercehealthcare.comForward shuts down one year after $100M funding roundNovember 13, 2024 | modernhealthcare.comPharma’s ethically questionable sites essentially sell drugs directly to consumersNovember 6, 2024 | statnews.comU.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain PartnersNovember 1, 2024 | msn.comPharmalittle: We’re reading about disappointing Lilly sales, a Roche Alzheimer’s therapy, and moreOctober 30, 2024 | statnews.comSangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory DevelopmentOctober 23, 2024 | seekingalpha.comWhy developers are turning to Forward Factory’s Code-to-Earn model (And why you should too)October 23, 2024 | msn.comFinland's largest energy company files €800 million lawsuit against RussiaOctober 22, 2024 | msn.comFirebrick Pharma’s Strategic Moves Boost Market PositionOctober 22, 2024 | markets.businessinsider.comThis Podiatrist Closed The $30 Million Gap Between Orthopedic And Fashion-Forward FootwearOctober 22, 2024 | forbes.comForward Air retains investment bankers to sell company, sources sayOctober 17, 2024 | freightwaves.comPharma 4.0: Shaping the Future of Pharmaceutical ManufacturingOctober 16, 2024 | news-medical.netIn the competitive world of pharma, companies need to focus on worker well-being to retain top talent, says Ferring's HR execOctober 16, 2024 | msn.comWest Pharmaceutical Services Honored with Heart of Pharma Award for Cancer PartnershipOctober 13, 2024 | msn.comFERMWORX Receives Department of Defense Award to Strengthen U.S. Supply Chains Through Bioindustrial ManufacturingOctober 11, 2024 | tmcnet.comForward Air ticks higher as activist Alta Fox pushes for strategic reviewOctober 8, 2024 | msn.comIronwood Pharmaceuticals: A Strong Buy on Financial Fortitude and Pipeline ProgressSeptember 30, 2024 | markets.businessinsider.comWIN Announces ‘Pay It Forward’ CampaignSeptember 26, 2024 | aftermarketnews.comFTC sues Big Pharma middlemen over skyrocketing insulin prices, targeting PBM practicesSeptember 25, 2024 | nationofchange.orgNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFWP, ACET, AVTX, and FBIO Company DescriptionsAdicet Bio NASDAQ:ACET$0.75 -0.03 (-3.80%) Closing price 04:00 PM EasternExtended Trading$0.75 0.00 (-0.04%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.Avalo Therapeutics NASDAQ:AVTX$4.84 -0.04 (-0.82%) Closing price 04:00 PM EasternExtended Trading$4.67 -0.17 (-3.60%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Fortress Biotech NASDAQ:FBIO$1.85 -0.11 (-5.61%) Closing price 04:00 PM EasternExtended Trading$1.94 +0.09 (+4.86%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Forward Pharma A/S NASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
